#Eli Lilly

What Eli Lilly’s Zepbound price cut signals for investors

Eli Lilly's price cut on Zepbound forces investors to weigh near-term revenue hits against potential higher adoption, insurer access, and long-term market share in obesity care.

Eli Lilly’s GLP‑1 Dominance and Lofty Valuation Make It a Hold

Eli Lilly leads the GLP‑1 revolution with strong sales and margins, but a premium valuation limits near-term upside—making the stock a sensible hold for many investors.